Histogen Inc.
Index- P/E- EPS (ttm)-3.52 Insider Own2.87% Shs Outstand4.28M Perf Week54.52%
Market Cap3.92M Forward P/E- EPS next Y-3.73 Insider Trans0.00% Shs Float4.15M Perf Month34.09%
Income-11.10M PEG- EPS next Q-1.11 Inst Own3.00% Short Float / Ratio0.24% / 0.01 Perf Quarter49.08%
Sales3.80M P/S1.03 EPS this Y55.60% Inst Trans53.31% Short Interest0.01M Perf Half Y-19.43%
Book/sh3.36 P/B0.42 EPS next Y-0.80% ROA-47.40% Target Price2.00 Perf Year-73.70%
Cash/sh4.35 P/C0.32 EPS next 5Y38.00% ROE-64.70% 52W Range0.76 - 9.40 Perf YTD69.88%
Dividend- P/FCF- EPS past 5Y50.90% ROI-73.90% 52W High-85.00% Beta1.35
Dividend %- Quick Ratio- Sales past 5Y-36.10% Gross Margin- 52W Low85.45% ATR0.16
Employees7 Current Ratio10.90 Sales Q/Q-20.00% Oper. Margin- RSI (14)72.64 Volatility23.00% 12.54%
OptionableNo Debt/Eq0.00 EPS Q/Q52.70% Profit Margin- Rel Volume2.10 Prev Close1.41
ShortableNo LT Debt/Eq0.00 EarningsMar 09 AMC Payout- Avg Volume985.07K Price1.41
Recom1.00 SMA2038.89% SMA5035.67% SMA200-10.76% Volume344,944 Change0.00%
Mar-16-23 04:05PM
Mar-09-23 04:05PM
Feb-27-23 04:15PM
Jan-03-23 04:05PM
Nov-10-22 04:15PM
04:05PM Loading…
Aug-11-22 04:05PM
Jul-27-22 04:05PM
Jul-14-22 04:05PM
Jul-12-22 11:40AM
Jun-01-22 04:00PM
May-17-22 04:05PM
May-12-22 04:05PM
Apr-28-22 04:05PM
Mar-25-22 04:05PM
Mar-23-22 08:00AM
04:05PM Loading…
Mar-10-22 04:05PM
Mar-03-22 04:15PM
Dec-21-21 06:19PM
Dec-16-21 08:00AM
Nov-26-21 05:11AM
Nov-10-21 04:05PM
Nov-08-21 04:05PM
Nov-02-21 08:00AM
Oct-27-21 08:00AM
Aug-31-21 04:05PM
Aug-16-21 08:00AM
Aug-11-21 04:05PM
Jul-29-21 04:05PM
Jul-28-21 04:05PM
Jun-30-21 08:00AM
08:00AM Loading…
Jun-22-21 08:00AM
Jun-09-21 04:01PM
Jun-07-21 04:05PM
Jun-03-21 08:00AM
May-19-21 08:00AM
May-13-21 04:01PM
Apr-28-21 04:05PM
Mar-30-21 08:00AM
Mar-25-21 04:05PM
Mar-16-21 08:00AM
Mar-15-21 08:00AM
Mar-11-21 04:01PM
Mar-10-21 04:05PM
Mar-04-21 04:05PM
Mar-02-21 08:00AM
Feb-16-21 08:00AM
Jan-19-21 04:05PM
Jan-07-21 09:46AM
Jan-06-21 08:00AM
Jan-05-21 04:05PM
Dec-30-20 10:25PM
Dec-17-20 08:00AM
Dec-01-20 08:00AM
Nov-16-20 04:05PM
Nov-12-20 08:00AM
Nov-10-20 04:05PM
Oct-28-20 04:30PM
Oct-27-20 08:00AM
Oct-19-20 08:00AM
Oct-05-20 08:00AM
Sep-29-20 08:00AM
Sep-16-20 08:00AM
Sep-10-20 08:00AM
Sep-01-20 04:15PM
Aug-13-20 04:05PM
Jul-30-20 04:15PM
Jul-29-20 04:15PM
Jul-20-20 04:10PM
Jul-14-20 05:00AM
Jun-03-20 08:00AM
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.